Collegium Pharmaceutical (COLL) Competitors $30.07 +0.21 (+0.70%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$30.07 0.00 (0.00%) As of 08/1/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock COLL vs. AKRO, ACLX, ACAD, VKTX, SRRK, PTCT, SWTX, MLTX, PTGX, and AAPGShould you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include Akero Therapeutics (AKRO), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), Scholar Rock (SRRK), PTC Therapeutics (PTCT), SpringWorks Therapeutics (SWTX), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Collegium Pharmaceutical vs. Its Competitors Akero Therapeutics Arcellx ACADIA Pharmaceuticals Viking Therapeutics Scholar Rock PTC Therapeutics SpringWorks Therapeutics MoonLake Immunotherapeutics Protagonist Therapeutics Ascentage Pharma Group International Akero Therapeutics (NASDAQ:AKRO) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability. Does the media refer more to AKRO or COLL? In the previous week, Akero Therapeutics and Akero Therapeutics both had 5 articles in the media. Akero Therapeutics' average media sentiment score of 1.29 beat Collegium Pharmaceutical's score of 0.52 indicating that Akero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akero Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, AKRO or COLL? Akero Therapeutics has a beta of -0.28, indicating that its stock price is 128% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Which has stronger valuation & earnings, AKRO or COLL? Collegium Pharmaceutical has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$252.06M-$1.95-24.81Collegium Pharmaceutical$631.45M1.53$69.19M$1.2224.65 Is AKRO or COLL more profitable? Collegium Pharmaceutical has a net margin of 6.61% compared to Akero Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 99.08% beat Akero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -15.19% -13.97% Collegium Pharmaceutical 6.61%99.08%15.14% Do analysts recommend AKRO or COLL? Akero Therapeutics currently has a consensus target price of $82.50, suggesting a potential upside of 70.56%. Collegium Pharmaceutical has a consensus target price of $43.75, suggesting a potential upside of 45.49%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Akero Therapeutics is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryCollegium Pharmaceutical beats Akero Therapeutics on 8 of the 12 factors compared between the two stocks. Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COLL vs. The Competition Export to ExcelMetricCollegium PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$959.46M$2.46B$5.49B$9.52BDividend YieldN/A1.81%4.73%4.09%P/E Ratio24.658.9728.7823.81Price / Sales1.53437.65372.2066.04Price / Cash2.42157.7635.4557.96Price / Book4.244.838.275.54Net Income$69.19M$31.62M$3.25B$259.28M7 Day Performance-5.38%-5.28%-3.70%-4.64%1 Month Performance-1.44%4.38%4.34%4.41%1 Year Performance-17.30%-2.49%25.90%17.95% Collegium Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COLLCollegium Pharmaceutical4.0314 of 5 stars$30.07+0.7%$43.75+45.5%-22.1%$959.46M$631.45M24.65210Upcoming EarningsAKROAkero Therapeutics3.9559 of 5 stars$49.24-2.6%$82.50+67.5%+83.6%$4.03BN/A-25.2530Positive NewsUpcoming EarningsACLXArcellx2.6029 of 5 stars$70.59-1.0%$111.23+57.6%+21.3%$3.93B$107.94M-23.6180News CoveragePositive NewsAnalyst ForecastACADACADIA Pharmaceuticals3.9847 of 5 stars$22.62-2.7%$28.13+24.3%+23.9%$3.89B$957.80M16.51510News CoverageUpcoming EarningsAnalyst RevisionVKTXViking Therapeutics3.8708 of 5 stars$33.20-3.5%$86.92+161.8%-40.2%$3.87BN/A-21.7020Short Interest ↑SRRKScholar Rock3.8123 of 5 stars$37.09-4.8%$42.67+15.0%+301.3%$3.70B$33.19M-14.66140News CoveragePositive NewsUpcoming EarningsAnalyst ForecastPTCTPTC Therapeutics4.4836 of 5 stars$44.36-0.9%$65.77+48.3%+59.5%$3.55B$806.78M6.811,410Trending NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionSWTXSpringWorks TherapeuticsN/A$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230Upcoming EarningsMLTXMoonLake Immunotherapeutics2.721 of 5 stars$54.47-1.1%$73.14+34.3%+25.9%$3.53BN/A-23.682News CoveragePositive NewsUpcoming EarningsPTGXProtagonist Therapeutics2.1526 of 5 stars$56.26+2.0%$66.10+17.5%+41.8%$3.42B$434.43M75.01120Positive NewsUpcoming EarningsAAPGAscentage Pharma Group InternationalN/A$39.27+3.9%N/AN/A$3.30B$134.35M0.00600 Related Companies and Tools Related Companies AKRO Competitors ACLX Competitors ACAD Competitors VKTX Competitors SRRK Competitors PTCT Competitors SWTX Competitors MLTX Competitors PTGX Competitors AAPG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COLL) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
